Health Economics & Decision Modelling
Sungkyunkwan University
Health Economics & Decision Modelling
Sungkyunkwan University
The Health Economics & Decision Modelling Lab generates policy-relevant evidence to support better health-care decisions. We integrate health economic evaluation, decision-analytic modelling, and real-world evidence (RWE) to assess the value of medicines, medical devices, and health services—answering practical questions about what works, for whom, at what cost, and under what conditions.
Our work spans the full evidence pathway: from defining decision problems with stakeholders, to building transparent models, to quantifying uncertainty, and to translating results into actionable insights for pricing, reimbursement, and resource allocation. We also emphasize patient-centred outcomes, including patient-reported outcomes (PROs), health-related quality of life (HRQoL), and health utility, to ensure that evaluations reflect outcomes that matter to patients and the public.
Research themes
Economic evaluation & HTA: cost-effectiveness/cost-utility analysis and budget impact analysis for medicines, devices, and services
Decision modelling: decision trees, state-transition models (e.g., Markov), microsimulation, and uncertainty/sensitivity analyses
Real-world evidence & outcomes research: healthcare big data–based effectiveness, safety, utilization, and cost studies
PROs, HRQoL & health utility: measurement, valuation, and application of patient-reported outcomes in economic evaluation
Pricing & reimbursement policy: evidence generation to inform coverage decisions and value-based policy design
We collaborate with academia, healthcare providers, public agencies, and industry partners to co-produce rigorous, transparent, and decision-ready evidence.
Study
Health economics foundations & policy context
Covers the core economic concepts used in healthcare and how they translate into policy decisions—why health systems need prioritisation, how incentives and market failures shape outcomes, and how economics supports resource allocation under budget constraints.
Economic evaluation methods (CEA/CUA) and interpretation
Teaches how to design and interpret economic evaluations of health technologies and services, including cost-effectiveness and cost-utility analysis, and how results are used within real decision-making guidelines and reimbursement processes.
Cost-effectiveness modelling for HTA (decision trees, Markov/state-transition models)
Focuses on building decision-analytic models to estimate long-term costs and outcomes when data are incomplete or follow-up is limited—structuring decision problems, selecting model types, populating input values, and critically appraising model assumptions and outputs.
Research methods, study design & systematic review skills
Builds practical skills in planning and evaluating health research, including quantitative/qualitative approaches and systematic review methods, with emphasis on producing evidence suitable for health technology evaluation (evaluating clinical evidence and combining results across studies—understanding RCT design and analysis, conducting meta-analysis, using frequentist and Bayesian approaches)
Health outcomes valuation (QALYs, utilities, preference-based measures; beyond-QALY issues)
Explains how health benefits are measured and valued for economic evaluation—utility measurement, preference-based instruments, deriving quality-adjustment weights for QALYs, and key debates such as capturing wider (non-health) benefits.
Advanced statistical methods for cost-effectiveness analysis (cost data, time-to-event, observational data)
Trains you to analyse common data types in applied health economics—skewed cost data, survival/time-to-event outcomes, and treatment effects from observational datasets—so estimates are credible for modelling and decision-making.
Advanced simulation modelling (including discrete-event simulation; model validation and interpretation)
Introduces simulation approaches for complex pathways and constrained resources—developing and validating simulation models (notably discrete-event simulation), exploring system dynamics, and interpreting outputs to inform policy and operational decisions.
약물경제 연구실은 의약품과 관련하여 더 나은 보건의료 의사결정을 지원하기 위해 정책 활용도가 높은 근거를 생산합니다. 의사결정분석 모형, 실사용근거(Real-World Evidence, RWE)를 통합하여 의약품, 의료기기, 보건의료서비스의 가치를 평가하고, “무엇이 누구에게 어떤 조건에서 얼마나 효과적이며, 비용은 어느 정도인가”라는 실질적 질문에 답합니다.
우리의 연구는 이해관계자와 함께 의사결정 문제를 정의하는 단계부터, 투명한 모형 구축, 불확실성 정량화, 그리고 결과를 약가·급여 및 자원배분 의사결정에 활용 가능한 통찰로 전환하는 전 과정을 포괄합니다. 또한 건강 관련 삶의 질(HRQoL), 효용(health utility) 등 환자 중심 성과를 평가하고 이를 반영 합니다.
경제성평가 & HTA: 의약품·의료기기·의료서비스의 비용-효과성/비용-효용 분석 및 재정영향 분석
의사결정모형: Decision tree, Markov model, microsimulation, 불확실성/민감도 분석
RWE & 성과연구: 보건의료 빅데이터 기반 효과·안전성·의료이용·비용 분석
PRO/HRQoL/건강효용: 환자보고성과의 측정·가치화 및 경제성평가 적용
약가·급여 정책: 급여/등재 의사결정 지원을 위한 근거 생성 및 가치 기반 정책 설계
학계, 의료기관, 공공기관, 산업계와 협력하여 엄밀하고 투명하며 의사결정에 바로 활용 가능한 근거를 공동 생산(co-production)하는 것을 지향합니다.